Evidence map›Paper›PMID 31315127›Full record

ArticleDementia and geriatric cognitive disorders2019

Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Achinoam Faust-Socher, Sarah Duff-Canning, Arthur Grabovsky, Melissa J Armstrong, Brandon Rothberg, Paul J Eslinger, Christopher A Meaney, Ruth B Schneider, David F Tang-Wai, Susan H Fox and 10 more

Open access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Dementia and geriatric cognitive disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Kinesiology training in patients with Parkinson's disease: results of a pilot study.Journal of neural transmission (Vienna, Austria : 1996) · 2020
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 2 countries.

Achinoam Faust-SocherThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada.
Sarah Duff-CanningThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada.
Arthur GrabovskyDepartment of Statistical Sciences, University of Toronto, Toronto, Ontario, Canada.
Melissa J ArmstrongDepartment of Neurology, University of Florida College of Medicine, Gainesville, Florida, USA.
Brandon RothbergThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada.
Paul J EslingerDepartments of Neurology, Neural and Behavioral Sciences, and Radiology, Penn State Hershey Medical Center, Hershey, Pennsylvania, USA.
Christopher A MeaneyDivision of Biostatistics, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
Ruth B SchneiderDepartment of Neurology, University of Rochester Medical Center, Rochester, New York, USA.
David F Tang-WaiDivision of Neurology, University Health Network Memory Clinic, University of Toronto, Toronto, Ontario, Canada.
Susan H FoxThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada.
Cindy ZadikoffDepartment of Neurology, Northwestern University, Chicago, Illinois, USA.
Nancy KennedyDepartment of Psychiatry and Behavioral Science, Northwestern University, Chicago, Illinois, USA.
Kelvin L ChouDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Carol PersadDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.
Irene LitvanParkinson and Other Movement Disorders Center, Department of Neuroscience, UC San Diego, San Diego, California, USA.
Benjamin T MastPsychological and Brain Sciences, University of Louisville, Louisville, Kentucky, USA.
Adam T GersteneckerDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sandra WeintraubDepartment of Psychiatry and Behavioural Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
William ReginoldThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada.
Connie MarrasThe Edmond J Safra Program in Parkinson's disease and the Morton and Gloria Shulman Movement Disorders Centre, University Health Network, Toronto, Ontario, Canada, connie.marras@utoronto.ca.
University Health Network · CANorthwestern University · USUniversity of Michigan–Ann Arbor · USUniversity of Toronto · CAPenn State Milton S. Hershey Medical Center · USUniversity of Alabama at Birmingham · USUniversity of California, San Diego · USUniversity of Florida · USUniversity of Louisville · USUniversity of Rochester Medical Center · US

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9M
NIA NIH HHS P30 AG013854
6 · The paper itself

Abstract

backgroundClinical monitoring of patients with Parkinson's disease (PD) for cognitive decline is an important element of care. The Montreal Cognitive Assessment (MoCA) has been proposed to be a sensitive tool for assessing cognitive impairment in PD. The aim of our study was to compare the responsiveness of the MoCA to decline in cognition to the responsiveness of the Mini Mental State Examination (MMSE) and the Scales for Outcomes of Parkinson's disease-cognition (SCOPA-Cog).

methodsPD patients without dementia were enrolled at 6 North American movement disorders centers between 2008 and 2011. Participants received annual evaluations including the MoCA, MMSE, and SCOPA-Cog followed by formal neuropsychological testing. The gold standard for change in cognition was defined as the change on the neuropsychological test scores over the annual assessments. The Reliable Change Method was used to provide an estimate of the probability that a given difference score would be obtained by chance. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change was quantified using receiver operating characteristics (ROC) curves.

resultsOne hundred seventeen patients were included in the analysis. Participants were followed at mean intervals of 11 ± 2 months for a median of 2 (maximum 5) visits. According to the reliable change index, 56 intervals of cognitive testing showed a decline in global cognition. ROC analysis of change in MoCA, MMSE, and SCOPA-Cog global scores compared to gold standard testing found an area under the curve (AUC) of 0.55 (95% CI 0.48-0.62), 0.56 (0.48-0.63), and 0.63 (0.55-0.70) respectively. There were no significant differences in the AUCs across the tests. The sensitivity of the MoCA, MMSE, and SCOPA-Cog to change at various thresholds for decline in scores reached a maximum of 71% for a cut-off of 1 point change on the SCOPA-Cog.

conclusionUsing neuropsychological testing as a gold standard comparator, the performance of the MoCA, MMSE, and SCOPA-Cog for detecting decline in non-demented PD patients over a 1-year interval is poor. This has implications for clinical practice; stable scores may not be taken as reassurance of the absence of cognitive decline.

Indexed as

Neuropsychological TestsAgedAged, 80 and overCognitionCognitive DysfunctionDementiaDisease ProgressionFemaleHumansMaleMental Status and Dementia TestsMiddle AgedParkinson DiseaseReproducibility of ResultsROC CurveSensitivity and SpecificityCognitive declineMild cognitive impairmentParkinson’s diseaseResponsiveness

Identifiers

PMID31315127
PMCPMC7186910
OpenAlexW2959353285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.